Bell Investment Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Bell Investment Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-363	Closed	-$1.98K	–	1909
2023 Q3	$1.98K	Sell	363 -79	-18%	-$522	﹤0.01%	1270
2023 Q2	$2.97K	Buy	442 +65	+17%	+$483	﹤0.01%	1096
2023 Q1	$3.33K	Sell	377 -90	-19%	-$793	﹤0.01%	986
2022 Q4	$3.57K	Sell	467 -149	-24%	-$1.16K	﹤0.01%	983
2022 Q3	$4K	Buy	616 +467	+313%	+$4.4K	﹤0.01%	744
2022 Q2	$1K	Buy	+149	New	+$1.31K	﹤0.01%	1303
2021 Q4	$4K	Sell	149 -67	-31%	-$2.05K	﹤0.01%	824
2021 Q3	$7K	Buy	+216	New	+$7.81K	﹤0.01%	550

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

AAP

Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Bell Investment Advisors's ADPT Position: Q4 2023 in Review

Bell Investment Advisors sold out of Adaptive Biotechnologies (ADPT) in Q4 2023, closing a stake of 363 shares — an estimated $1.98K sold.

Bell Investment Advisors first reported a position in ADPT in Q3 2021 and held it in 8 quarters. The position peaked at $7K in Q3 2021. 200 funds tracked by Wall St. Rank hold ADPT as of Q4 2023.

Bell Investment Advisors reported no remaining Adaptive Biotechnologies position as of Q4 2023 after selling out during the quarter.
Bell Investment Advisors sold 363 Adaptive Biotechnologies shares in Q4 2023, an estimated $1.98K.
Bell Investment Advisors first reported a position in Adaptive Biotechnologies in Q3 2021 and held it in 8 quarters.
Bell Investment Advisors's Adaptive Biotechnologies position peaked at $7K in Q3 2021.
200 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2023.

Based on Bell Investment Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.